RUA Life Sciences reports 6% revenue growth in first half

RUA Life Sciences reported 6% revenue growth for the six months ended March 31, 2026, to £2.8 million, with gross margin edging up to 75% and administrative costs down 8% to £2.3 million. The company expects to reach EBITDA breakeven on an adjusted basis, helped by a £3 million convertible loan note fundraise and the spinout of its structural heart business, which should deliver a ~£0.5 million net cash benefit. Revenue remained mixed across divisions, as Abiss sales fell 23% while the UK CDMO business rose 32% and biomaterials revenue increased 41%.

Analysis

The key signal is not the modest top-line improvement; it is the business model cleanup. Management has effectively de-risked the P&L by shedding a structurally cash-leaky segment and replacing it with a more visible mix of contract development work and royalty catch-up revenue. That should improve valuation quality because the market can now underwrite a narrower, less capital-intensive earnings stream rather than a conglomerate discount tied to an underperforming device franchise.

The near-term winner is the balance sheet, not the income statement. The fresh financing plus the structural-heart spinout likely buys several quarters of runway, but the real second-order effect is bargaining power with suppliers and customers: a cleaner cost base should make it easier to win smaller development mandates without needing to subsidize them with central overhead. The flip side is that the outperformance in biomaterials is partly non-recurring, so the market may over-earn the run-rate if it capitalizes the current period too aggressively.

Catalyst-wise, the next 1-2 months matter more than the next year: interim accounts will determine whether EBITDA breakeven is credible on a standalone basis after stripping out one-offs. If the next report shows sequential conversion of the announced contract backlog and no further inventory destocking at the France unit, the stock can re-rate as a turnaround story; if not, the post-spin funding event will look more like a bridge than a cure. The biggest risk is that customer concentration remains high enough that one buyer decision can still swamp operational improvements.

Contrarian view: the market may be anchoring on the headline revenue growth and missing that the business is becoming smaller but more financeable. That is usually positive for equity optionality, but only if the remaining units can sustain mid-single-digit organic growth without further exceptional items. In other words, this is less a growth story than a survivability and operating leverage story, and that distinction matters for how much multiple expansion is justified.

Key Decisions for Investors

• Long NDRA on a 1-3 month horizon only if interim accounts confirm EBITDA breakeven ex non-cash and non-recurring items; target a 20-30% re-rating on cleaner cash-flow visibility, stop if cash burn remains near prior run-rate.
• Use any post-financing strength to fade strength with a tactical short if the stock trades as if the royalty audit uplift is recurring; asymmetry favors limited upside if the next update lacks new contract wins.
• Pair trade: long NDRA vs short a more levered healthcare microcap with ongoing cash burn, to isolate the benefit of balance-sheet repair and reduce sector beta.
• If liquidity allows, buy short-dated call spreads into the June interim release; the setup is event-driven, with upside from a credible turnaround narrative but capped by the risk that the France division keeps dragging.